Novartis Reports Results of Kisqali in P-III MONALEESA-7 Trial to Treat HR+/HER2- Metastatic Breast Cancer
Shots:
- The P-III MONALEESA-7 trial involves assessing Kisqali + endocrine therapy (goserelin + either an aromatase inhibitor or tamoxifen) as initial treatment vs endocrine therapy alone in patients with HR+/HER2- m-BC
- Result: @53.5 mos. follow-up- m-OS (58.7 vs 48.0 mos.); similar m-OS (58.7 vs 47.7 mos.) observed in IIT population; @ 42 mos. follow-up- estimated survival rate (70.2% vs 46%)
- The US FDA and EC has approved Kisqali in Mar’2017 and Aug’2017 as initial endocrine-based therapy for postmenopausal women with HR+/HER2- LA/m-BC in combination with an aromatase inhibitor based on findings from the pivotal MONALEESA-2 trial
Ref: PRNewswire | Image: Novartis
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com